TrialOpen forum infectious diseases2026

Similar Efficacy, Safety, and Immune Improvement Through 96 Weeks in Individuals With Limited HIV-1 Treatment Options Using Twice-Daily Dolutegravir- or Fostemsavir-based Regimens.

Antonella Castagna et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.